Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

ISMPP EU

- PMLiVE

Genentech increases investment to $2bn for US manufacturing site

Roche and Genentech have a current commitment of $50bn for US manufacturing

- PMLiVE

Connecting through the chaos – why medical affairs needs creative problem-solving

By Ali Walsh

- PMLiVE

Genentech reports positive trial results for obesity treatment

The treatment is designed to tackle obesity by reducing appetite and regulating blood sugar

- PMLiVE

GC Therapeutics appoints Kate Haviland as Board Chair

Haviland was most recently President and CEO of Blueprint Medicines

- PMLiVE

Novo Nordisk and Aspect Biosystems expand collaboration on diabetes research

The companies are working together on cellular medicines to boost, replace or repair biological functions

- PMLiVE

AstraZeneca announces $15bn investment in Chinese manufacturing and R&D by 2030

The pharma company will be the first global biopharma with end-to-end cell therapy capabilities in China

- PMLiVE

Ipsen appoints Pierrick Lefranc as Executive Vice President Technical Operations

Lefranc has served at Ipsen since 2013, most recently as Senior Vice President

- PMLiVE

Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

- PMLiVE

GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults

RSV affects approximately 64 million people around the world each year

- PMLiVE

Emotive appoints Terri Cooper as chair of the board and Mark Swindell as non-executive director

Terri and Mark both have extensive life sciences and consulting experience

- PMLiVE

ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment

In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on...

Genesis Research Group

- PMLiVE

Eisai and Biogen’s subcutaneous Leqembi given FDA Priority Review for early Alzheimer’s

Administering the drug subcutaneously rather than intravenously showed similar clinical benefits for patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links